[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-cyst\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-cyst":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,68,92,118,141,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100436960","pancreatic-cancer-early-detection-consortium-100436960",false,"NCT04970056","Pancreatic Cancer Early Detection Consortium","PRECEDE","Inclusion Criteria:\n\nIndividuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:\n\nCohort 1\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.\n2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+\n5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+\n6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+\n\nCohort 2\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+\n2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family\n3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member\n\nCohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)\n\nCohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.\n\nCohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and\u002For buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.\n\nCohort 6a\n\nIndividuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n\nCohort 6b\n\nIndividuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n3. Diagnosed ≤ age 45\n\nCohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.\n\nCohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.\n\nCyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)\n\nExclusion Criteria:\n\n* Individuals not meeting the criteria above.",true,"ALL","18 Years","90 Years",{"count":21,"type":22},20000,"ESTIMATED","OBSERVATIONAL","The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and\u002For individuals carrying pathogenic\u002Flikely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.",[26,27,28,29],"Pancreas Cancer","Pancreas Cyst","Pancreatic Ductal Adenocarcinoma","Genetic Predisposition","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2020-09-18",{"date":38,"type":22},"2030-12-31",{"name":40,"class":41},"Arbor Research Collaborative for Health","OTHER",60,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100326955","tumour-regulatory-molecules-in-early-pancreatic-cancer-detection-100326955","NCT03536793","Tumour Regulatory Molecules in Early Pancreatic Cancer Detection","Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions","TEM-PAC","Inclusion Criteria:\n\nGeneral\n\n* Capable of giving written informed consent\n* Age ≥18 years\n\nPancreatic Cancer Cohort\n\n\\- Diagnosed with localised pancreatic cancer amenable to resection (distal pancreatectomy, total pancreatectomy or Whipple's procedure).\n\nOR - Diagnosed with inoperable localised pancreatic cancer and referred for further management (malignant control subgroup).\n\nPancreatic Cysts Cohort\n\n\\- Presence of cystic lesions where MDT have agreed further diagnostic intervention procedures (including FNA\u002FEUS) necessary.\n\nOR - Patient the MDT have agreed have resectable lesions suspicious for pancreatic malignancy and going to surgery.\n\nBenign Cohort\n\n\\- Referral for endoscopic cystogastrostomy for complicated acute pancreatitis characterised by peripancreatic fluid collections and pseudocysts in development or matured (non-resolving and requiring further intervention).\n\nOR\n\n* Referral for cholecystectomy for cholocystitis\u002Fchololethiasis. OR\n* Patient planned to have endoscopy investigation for dyspepsia (normal control subgroup).\n\nExclusion Criteria:\n\nGeneral\n\n* Inability to provide written informed consent\n* Other known malignant condition, either active or in complete remission ≤5 years\n* HIV, hepatitis C, or any other known communicable disease",{"count":52,"type":22},180,"The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pancreatic cancer, at a stage where surgery is feasible, would greatly increase the 5-year survival rate. Detecting pancreatic cancer early is therefore vital to improve the prognosis for these patients.\n\nPre-cancerous pancreatic cysts are an early indicator of malignant transformation. The ideal screening test would be capable of detecting pancreatic cancer at these initial stages. Current procedures for pancreatic cancer diagnosis are invasive, uncomfortable and costly, and can be considered unnecessary in those cysts found to be benign.\n\nWe propose to study a number of tumour regulatory molecules that have been the subject of research in laboratories at the University of Hull (e.g., tissue factor (TF), adrenomedullin (AM) using enzyme-linked immunosorbent assays (ELISA) tests) that have been studied in the context of carcinogenic transformation in more common malignancies but have yet to be fully tested in pancreatic malignant transformation. The recent introduction of platform technologies at the University of Hull has broadened this area of investigation by giving us access to next generation genomic sequencing and proteomic analyses of small amounts of tissue samples. We intend to analyse pancreatic cystic fluid samples using these technologies to discover new regulatory molecules.\n\nAltogether, his study will measure the levels of novel regulatory molecules and genetic changes involved with pancreatic cancer carcinogenesis using a combination of conventional techniques (e.g. ELISA) and state-of-the-art platform technologies in pancreatic cysts from those patients in whom cancer may be suspected, to determine the potential of these molecules to serve as markers to detect early changes towards pancreatic cancer.",[55,27],"Cancer of Pancreas",[57],"Early detection of pancreatic cancer","2026-06-22",{"date":31,"type":34},{"date":61,"type":34},"2018-10-24",{"date":63,"type":22},"2029-02-28",{"name":65,"class":66},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":67},"100351435","molecular-detection-of-advanced-neoplasia-in-pancreatic-cysts-100351435","NCT03855800","Molecular Detection of Advanced Neoplasia in Pancreatic Cysts","Molecular Detection of Advanced Neoplasia in Pancreatic Cysts (IN-CYST)","Inclusion Criteria:\n\n* Patients with pancreatic cystic lesions meeting Fukuoka worrisome or Fukuoka high-risk criteris\n* Patients with suspected cystic neoplasm of the pancreas\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant and\u002For nursing\n* Incarceration\n* Imaging showing possible pancreatic cancer\n* Prior history of pancreatic cancer or pancreatic surgery\n* History of receiving systemic chemotherapy or abdominal radiation within the last 5 years\n* Previous therapy for a pancreatic cystic lesion\n* History of pancreatic necrosis\n* Diagnosis of cancer (other than non-melanoma skin cancer) within the last 5 years","120 Years",{"count":77,"type":22},800,"INTERVENTIONAL",[80],"NA","Researchers are trying to find out whether new tests (\"biomarkers\") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.",[27],"2026-05-29",{"date":85,"type":34},"2026-06-02",{"date":87,"type":34},"2018-05-11",{"date":89,"type":22},"2030-12-30",{"name":91,"class":41},"Mayo Clinic",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":16,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":67},"100329392","blood-markers-of-early-pancreas-cancer-100329392","NCT03568630","Blood Markers of Early Pancreas Cancer","A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer","Inclusion Criteria:\n\n* Age ≥19\n* Able to provide written, informed consent\n* Able to attend an in-person study visit in Omaha, NE twice a year to collect blood samples\n* Must also meet criteria for one specific cohort. Participants who meet criteria for more than one cohort are eligible. (The intent being that potential participants must meet the criteria for at least one cohort, but are eligible if criteria are met for more than one cohort)\n\n  o New onset diabetes\u002Fhigh-risk pre-diabetes cohort: must meet one of the following criteria: New onset type 2 diabetes diagnosed within the past 3 years, defined as A1c ≥ 6.5%, fasting blood glucose \\>126mg\u002FdL confirmed on a subsequent day or as diagnosed by a physician High-risk pre-diabetes: A1c \\>6.3% or A1c \\>6.0% with fasting blood glucose \\>110 or 2 hour oral glucose tolerance test between 140-200mg\u002FdL, or taken metformin \\\u003C3 years\n\n  o Pancreatic cystic neoplasm\u002Fpancreatitis cohort: must have one of the following diagnoses: Pancreatic cystic neoplasm for which resection, endoscopic ultrasound (EUS) or serial imaging has been recommended Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist\n\n  o Inherited risk cohort: must meet one of the following criteria: Two or more blood relatives with pancreatic ductal adenocarcinoma (PDAC), includes 1st-3rd degree relatives (First - parent, sibling or child; Second - grandparent, aunt\u002Funcle, niece\u002Fnephew, or half-sibling; Third - first cousin, great grand parent or great grandchild) One 1st degree relative with PDAC diagnosed before age 60; Germline mutation associated with a higher than average risk of PDAC, including but not limited to: Hereditary breast and ovarian cancer syndromes (BRCA1, BRCA2, PALB2) Hereditary nonpolyposis colon cancer (Lynch) syndrome (MLH1, MSH2, MSH6, PMS2) Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome (CKDN2a, p16) Peutz-Jeghers syndrome (STK11) Ataxia-telangectasia (ATM) Juvenile polyposis syndromes (SMAD4, BMPR1A) Li Fraumeni (TP53) Cystic fibrosis and unaffected carriers (CFTR) Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC (as above)\n\nExclusion Criteria:\n\n* Personal history of pancreatic ductal adenocarcinoma (PDAC)\n* Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)\n* Pre-diabetes on metformin for ≥ 3 years","19 Years",{"count":101,"type":22},1250,"Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.\n\nThe investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.",[104,105,27,106,107,108],"Diabetes Mellitus, Type 2","PreDiabetes","Chronic Pancreatitis","Genetic Predisposition to Disease","Inherited Disease","2026-01-29",{"date":111,"type":34},"2026-02-02",{"date":113,"type":34},"2018-07-26",{"date":115,"type":22},"2028-07",{"name":117,"class":41},"University of Nebraska",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":67},"100494125","radiology-registry-on-pancreatic-malignancies-100494125","NCT05714111","Radiology Registry on Pancreatic Malignancies","RadonPams","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage.\n* able and willing to sign informed consent\n\nExclusion Criteria:\n\n* Patients with non-primary pancreatic disease",{"count":126,"type":22},1300,"The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and prospective data until 2027 with a maximum follow-up of 3 years per patient.",[129,130,131,27],"Pancreatic Cancer","Pancreas Neoplasm","Pancreas Disease","2024-04-11",{"date":134,"type":34},"2024-04-12",{"date":136,"type":34},"2022-03-04",{"date":138,"type":22},"2030-03-30",{"name":140,"class":41},"IRCCS San Raffaele",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":156,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":67},"100520318","improving-pancreatic-cancer-care-by-the-use-of-computational-science-and-technology-100520318","NCT06055010","Improving Pancreatic Cancer Care by the Use of Computational Science and Technology","IMPACT","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients who received diagnostic procedures and\u002For treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database and healthy individuals who received an abdominal CT-scan (controls)\n\nExclusion Criteria:\n\n\\- Subjects who object to the use of their data for the purpose of scientific research",{"count":149,"type":22},5000,"The goal of the IMPACT project is to set up a data sharing infrastructure between expert centers for pancreatic surgery that enables training, testing and validation of computer science tools to improve quality of care for patients with pancreatic cancer.",[129,152,153,154,155,27],"Pancreatic Cyst","Pancreatic Adenocarcinoma","Pancreatic Diseases","Pancreas Adenocarcinoma",[157,158,159,129],"Artificial Intelligence","Data Science","Computer Science","2023-09-22",{"date":162,"type":34},"2023-09-26",{"date":164,"type":34},"2014-01-01",{"date":166,"type":22},"2029-12-31",{"name":168,"class":41},"UMC Utrecht",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":178,"studyType":23,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":67},"100451236","prognostic-factors-in-periampullary-tumors-and-cysts-100451236","NCT05155878","Prognostic Factors in Periampullary Tumors and Cysts","Prognostic Factors, Operative Care and Short and Long Term Outcomes for Cysts and Tumors in Pancreas and the Periampullary Region","Inclusion Criteria:\n\n* Recommended surgery for tumor or cyst in the pancreas or periampullary region\n* Information avalible in electronic journal files\n* Informed consent (or deceased for retrospective part of the study)\n\nExclusion Criteria:\n\n* No informed consent (and still alive at study initiation)",{"count":177,"type":22},500,"10 Years","The project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for biomarker development and validation.",[26,130,27,181,131,182,183,184,185],"Pancreatic Fistula","Bile Duct Cancer","Periampullary Cancer","Surgery","Surgery--Complications","2021-12-13",{"date":188,"type":34},"2022-01-05",{"date":190,"type":34},"2021-09-01",{"date":192,"type":22},"2040-01-01",{"name":194,"class":41},"Umeå University"]